TP53 and myelodysplastic syndrome: Despite being one of the most studied genes since its discovery, TP53 is considered “undruggable.” Therefore, TP53-mutated MDS remains a long-standing therapeutic challenge, with a median survival of only 5–10 months, irrespective of the therapies administered (14).